255 results on '"Finetti, Pascal"'
Search Results
2. Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer
3. Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
4. Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network
5. Mechanistic modeling of metastatic relapse in early breast cancer to investigate the biological impact of prognostic biomarkers
6. Axin1 Protects Colon Carcinogenesis by an Immune-Mediated Effect
7. Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity
8. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
9. Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC
10. BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells
11. EFA6B regulates a stop signal for collective invasion in breast cancer
12. The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
13. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma
14. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
15. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity
16. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer
17. ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer
18. The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
19. The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
20. Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)
21. Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation
22. Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer
23. The MonarchE trial: improving the clinical outcome in HR+/HER2− early breast cancer: recent results and next steps.
24. Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer.
25. ZNF703 mRNA-Targeting Antisense Oligonucleotide Blocks Cell Proliferation and Induces Apoptosis in Breast Cancer Cell Lines.
26. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
27. Genomic profiling of inflammatory breast cancer: A review
28. An OMA1 redox site controls mitochondrial homeostasis, sarcoma growth, and immunogenicity.
29. SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer.
30. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a
31. Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype.
32. PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma.
33. CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction
34. ESPL1 is a candidate oncogene of luminal B breast cancers
35. TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT.
36. Pediatric mastocytosis–associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations
37. Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease
38. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer
39. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome
40. HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers
41. MARCKS as a Potential Therapeutic Target in Inflammatory Breast Cancer.
42. CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness.
43. Low cholesterol biosynthesis favors epithelial‐to‐mesenchymal transition maintenance and influences tumor molecular subtyping and disease‐free survival in colon cancer patients.
44. CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression.
45. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents
46. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer
47. A gene expression signature identifies two prognostic subgroups of basal breast cancer
48. Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial.
49. Ketogenic HMG‐CoA lyase and its product β‐hydroxybutyrate promote pancreatic cancer progression.
50. High Frequency of Chromosome 14 Deletion in Early-Onset Colon Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.